MedTrace Logo

Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects

NCT00949767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2011-01-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.

Conditions

Interventions

DRUG

BMS-866949

(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days

DRUG

Placebo

(Matching volume) - Oral Solution, Oral, once 14 days

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949767 on ClinicalTrials.gov